Capricor Therapeutics (NASDAQ:CAPR) Cut to Sell at Wall Street Zen

Capricor Therapeutics (NASDAQ:CAPR) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued on Sunday.

CAPR has been the subject of several other research reports. UBS Group set a $50.00 price objective on shares of Capricor Therapeutics in a research report on Monday, December 15th. Piper Sandler restated an “overweight” rating and issued a $45.00 target price (up from $20.00) on shares of Capricor Therapeutics in a research report on Wednesday, December 10th. Oppenheimer upped their price target on shares of Capricor Therapeutics from $22.00 to $54.00 and gave the stock an “outperform” rating in a report on Monday, December 8th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Capricor Therapeutics in a research report on Monday, December 29th. Finally, HC Wainwright boosted their price objective on shares of Capricor Therapeutics from $24.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, December 3rd. Nine equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Capricor Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $40.82.

Capricor Therapeutics Price Performance

NASDAQ CAPR opened at $23.84 on Friday. The firm has a market cap of $1.09 billion, a P/E ratio of -13.24 and a beta of 0.22. Capricor Therapeutics has a fifty-two week low of $4.30 and a fifty-two week high of $40.37. The stock’s 50-day moving average is $17.95 and its two-hundred day moving average is $11.07.

Capricor Therapeutics (NASDAQ:CAPR) last announced its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($0.54) earnings per share for the quarter, meeting the consensus estimate of ($0.54). On average, equities analysts expect that Capricor Therapeutics will post -1.21 EPS for the current year.

Hedge Funds Weigh In On Capricor Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Goldman Sachs Group Inc. boosted its position in Capricor Therapeutics by 39.5% in the first quarter. Goldman Sachs Group Inc. now owns 411,141 shares of the biotechnology company’s stock valued at $3,902,000 after buying an additional 116,373 shares in the last quarter. Rhumbline Advisers lifted its stake in shares of Capricor Therapeutics by 8.1% in the 1st quarter. Rhumbline Advisers now owns 49,814 shares of the biotechnology company’s stock valued at $473,000 after acquiring an additional 3,731 shares during the last quarter. Krilogy Financial LLC boosted its holdings in shares of Capricor Therapeutics by 78.9% during the 2nd quarter. Krilogy Financial LLC now owns 40,800 shares of the biotechnology company’s stock valued at $405,000 after acquiring an additional 18,000 shares in the last quarter. KLP Kapitalforvaltning AS boosted its holdings in shares of Capricor Therapeutics by 65.2% during the 2nd quarter. KLP Kapitalforvaltning AS now owns 10,900 shares of the biotechnology company’s stock valued at $108,000 after acquiring an additional 4,300 shares in the last quarter. Finally, VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in Capricor Therapeutics during the 2nd quarter worth $135,000. Institutional investors own 21.68% of the company’s stock.

About Capricor Therapeutics

Capricor Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of cell and exosome-based therapeutics for cardiovascular and rare diseases. Headquartered in Beverly Hills, California, the company leverages proprietary cardiosphere-derived cell (CDC) technology to address conditions characterized by inflammation, fibrosis, and tissue degeneration. Since its founding, Capricor has advanced its lead candidate through multiple clinical trials and has built a pipeline that spans both cell therapy and extracellular vesicle (exosome) platforms.

The company’s leading product candidate, CAP-1002, comprises allogeneic CDCs and is being evaluated in indications such as Duchenne muscular dystrophy (DMD) and COVID-19-related heart injury.